Replies to post #143388 on Biotech Values

[ghmm]

CELG CVR:

Is the NSCLC with a PFS label unlikely because tumor shrinkage will not correlate with PFS and that won't be in the label or some other reason?

I've been looking at the CVR a bit more and it seems they had an agreement with FDA (not sure if they had a SPA or not) so I got the impression NSCLC approval was a possibility despite no survival benefit.

I'm trying to figure if Abraxane could get to 1-2billion in sales that would be a real nice stream for the CVR if it could.